^
    24h
    Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (clinicaltrials.gov)
    P1, N=94, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    carboplatin • paclitaxel • veliparib (ABT-888)
    1d
    MiRaDoR: A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population (clinicaltrials.gov)
    P2, N=976, Recruiting, MedSIR | Trial completion date: Dec 2028 --> Jun 2028 | Trial primary completion date: Dec 2028 --> Jun 2028
    Trial completion date • Trial primary completion date • Minimal residual disease • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint®
    |
    Verzenio (abemaciclib) • Itovebi (inavolisib) • giredestrant (RG6171)
    1d
    A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) (clinicaltrials.gov)
    P3, N=541, Active, not recruiting, DualityBio Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • mTOR (Mechanistic target of rapamycin kinase)
    |
    HER-2 positive • HER-2 expression • HER-2 underexpression
    |
    capecitabine • albumin-bound paclitaxel • trastuzumab pamirtecan (BNT323)
    1d
    Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer (clinicaltrials.gov)
    P=N/A, N=350, Suspended, City of Hope Medical Center | Initiation date: Jan 2026 --> May 2026
    Trial initiation date • Minimal residual disease • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    2d
    Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
    P3, N=5018, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2032 --> Jan 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    2d
    Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study. (PubMed, Breast Cancer Res)
    Chidamide combined with fulvestrant showed encouraging antitumor activity and tolerable toxicity in pts with HR + /HER2- advanced breast cancer that had progressed after previous endocrine therapy. Trial registration ChiCTR2100044282, registered on March 14th 2021.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    fulvestrant • Epidaza (chidamide)
    2d
    MEHP promotes breast cancer progression via GPR30-mediated epithelial-mesenchymal transition. (PubMed, Food Chem Toxicol)
    Notably, GPR30 inhibition attenuated MEHP-induced promotion of MCF-7 cell proliferation and migration through modulating of EMT process.
    Journal
    |
    GPER1 (G Protein-Coupled Estrogen Receptor 1)
    |
    HR positive
    2d
    Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease. (PubMed, Ann Oncol)
    These data support T-DXd as a broadly efficacious treatment for patients with HR+, HER2-low/-ultralow mBC after ≥1 ET, regardless of TTP on prior first-line ET + CDK4/6i, endocrine resistance, or disease burden.
    Journal • HEOR
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    2d
    Overexpression of TFF3 is Associated with Immune Infiltration, Molecular Subtypes, and Clinical Progression in Breast Cancer. (PubMed, Curr Med Sci)
    TFF3 is a robust diagnostic biomarker for BRCA molecular subtyping, an independent prognostic factor, and a potential immunomodulator. These findings highlight its clinical utility for patient stratification and potential as a therapeutic target, particularly in hormone receptor-positive BRCA.
    Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • BRCA (Breast cancer early onset) • TFF3 (Trefoil factor 3)
    |
    HR positive
    3d
    Characteristic Hepatic Atrophy in Abemaciclib-Induced Liver Injury: A Comparative Review of Three Cases. (PubMed, Hepatol Res)
    This report is the first highlighting the imaging characteristics of rapid-onset hepatic atrophy associated with abemaciclib-induced liver injury. These findings may provide useful insights for distinguishing abemaciclib-induced liver injury from other etiologies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole
    3d
    NATALEE: A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (clinicaltrials.gov)
    P3, N=5101, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: May 2026 --> May 2030 | Trial primary completion date: May 2026 --> May 2030
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint® • EndoPredict®
    |
    Kisqali (ribociclib)
    3d
    Study on the Safety and Tolerability of Postoperative Radiotherapy Concurrent With CDK4/6 Inhibitors in HR+/HER2- High-Risk Breast Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Guizhou Provincial People's Hospital
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative